A phase II trial of intrathecal pemetrexed in patients with EGFR-mutated NSCLC who had progressed on TKIs demonstrated a response rate of 80.3% with acceptable side effects [168]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.